SCHEMBL774060

SCHEMBL774060

CC(C(=O)O)n1c(CNC(=O)c2ccc3c(C4CCCCC4)c4n(c3c2)CCOc2ccccc2-4)nc2ccccc21

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PRKCA P17252 1/20 0.48
MMP12 P39900 1/20 0.48
NR1I2 O75469 1/20 0.39
SCN9A Q15858 2/20 0.37
LMNA P02545 3/20 0.37
HDAC6 Q9UBN7 1/20 0.36
RPS6KA3 P51812 2/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
HTT P42858 1/20 0.35
RPS6KA2 Q15349 3/20 0.35
KDM4E B2RXH2 1/20 0.34
ALDH1A1 P00352 1/20 0.34
GAA P10253 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
TP53 P04637 2/20 0.34
MAPT P10636 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL774322 0.89 PRKCA (0.47) PRKCAMMP12NR1I2SCN9ALMNA
SCHEMBL774451 0.87 PRKCA (0.46) PRKCAMMP12NR1I2SCN9ALMNA
SCHEMBL772565 0.86 PRKCA (0.44) PRKCAMMP12NR1I2SCN9ARPS6KA3
SCHEMBL773811 0.86 PRKCA (0.44) PRKCAMMP12NR1I2SCN9ALMNA
SCHEMBL12429005 0.85 PRKCA (0.44) PRKCAMMP12NR1I2SCN9ALMNA
SCHEMBL774557 0.81 PRKCA (0.54) PRKCAMMP12NR1I2SCN9ALMNA
SCHEMBL774547 0.81 PRKCA (0.53) PRKCAMMP12NR1I2SCN9AHDAC6
SCHEMBL773448 0.81 PRKCA (0.54) PRKCAMMP12NR1I2SCN9ALMNA
SCHEMBL772489 0.81 ROCK2 (0.48) PRKCAMMP12NR1I2SCN9AKMT2A
SCHEMBL772443 0.80 PRKCA (0.43) PRKCAMMP12NR1I2SCN9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120070409-A1 TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR JAPAN TOBACCO INC. (JP) 2012-03-22 US disclosed
US-7977331-B1 Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor JAPAN TOBACCO INC. (JP) 2011-07-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120070409-A1 TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR POLI, TERT, ZC3HAV1 PRKCA 2404/4885MMP12 1013/4885NR1I2 1189/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.